{"id":783,"date":"2025-07-07T08:48:00","date_gmt":"2025-07-07T06:48:00","guid":{"rendered":"https:\/\/gxb.webs.uvigo.es\/?p=783"},"modified":"2026-10-20T08:51:08","modified_gmt":"2026-10-20T06:51:08","slug":"new-paper-in-nature-communications-connexin43-as-a-new-target-to-overcome-drug-resistance-in-cancer","status":"publish","type":"post","link":"https:\/\/gxb.webs.uvigo.es\/?p=783","title":{"rendered":"New paper in Nature Communications: Connexin43 as a new target to overcome drug resistance in cancer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">We published a study in\u00a0<em>Nature Communications<\/em>\u00a0identifying connexin43 (Cx43) as a new therapeutic target in BRAF-mutant tumors such as melanoma, colorectal cancer, and breast cancer. Restoring Cx43 enhances the efficacy of BRAF\/MEK inhibitors and can reverse drug resistance. The team also developed a patented mRNA-based therapy delivered through nanovesicles.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><br><a href=\"https:\/\/www.nature.com\/articles\/s41467-025-60971-3\" target=\"_blank\" rel=\"noopener\">https:\/\/www.nature.com\/articles\/s41467-025-60971-3<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1011\" height=\"1024\" data-attachment-id=\"784\" data-permalink=\"https:\/\/gxb.webs.uvigo.es\/?attachment_id=784\" data-orig-file=\"https:\/\/gxb.webs.uvigo.es\/wp-content\/uploads\/2026\/10\/image.png\" data-orig-size=\"1977,2002\" data-comments-opened=\"0\" data-image-title=\"image\" data-image-description=\"\" data-image-caption=\"\" data-large-file=\"https:\/\/gxb.webs.uvigo.es\/wp-content\/uploads\/2026\/10\/image-1011x1024.png\" src=\"https:\/\/gxb.webs.uvigo.es\/wp-content\/uploads\/2026\/10\/image-1011x1024.png\" alt=\"\" class=\"wp-image-784\" srcset=\"https:\/\/gxb.webs.uvigo.es\/wp-content\/uploads\/2026\/10\/image-1011x1024.png 1011w, https:\/\/gxb.webs.uvigo.es\/wp-content\/uploads\/2026\/10\/image-296x300.png 296w, https:\/\/gxb.webs.uvigo.es\/wp-content\/uploads\/2026\/10\/image-767x777.png 767w, https:\/\/gxb.webs.uvigo.es\/wp-content\/uploads\/2026\/10\/image-1517x1536.png 1517w, https:\/\/gxb.webs.uvigo.es\/wp-content\/uploads\/2026\/10\/image-100x100.png 100w, https:\/\/gxb.webs.uvigo.es\/wp-content\/uploads\/2026\/10\/image.png 1977w\" sizes=\"auto, (max-width: 767px) 89vw, (max-width: 1000px) 54vw, (max-width: 1071px) 543px, 580px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>We published a study in\u00a0Nature Communications\u00a0identifying connexin43 (Cx43) as a new therapeutic target in BRAF-mutant tumors such as melanoma, colorectal cancer, and breast cancer. Restoring Cx43 enhances the efficacy of BRAF\/MEK inhibitors and can reverse drug resistance. The team also developed a patented mRNA-based therapy delivered through nanovesicles. https:\/\/www.nature.com\/articles\/s41467-025-60971-3<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[1],"tags":[],"class_list":["post-783","post","type-post","status-publish","format-standard","hentry","category-sin-categoria"],"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pag62I-cD","jetpack-related-posts":[],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/gxb.webs.uvigo.es\/index.php?rest_route=\/wp\/v2\/posts\/783","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/gxb.webs.uvigo.es\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/gxb.webs.uvigo.es\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/gxb.webs.uvigo.es\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/gxb.webs.uvigo.es\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=783"}],"version-history":[{"count":2,"href":"https:\/\/gxb.webs.uvigo.es\/index.php?rest_route=\/wp\/v2\/posts\/783\/revisions"}],"predecessor-version":[{"id":786,"href":"https:\/\/gxb.webs.uvigo.es\/index.php?rest_route=\/wp\/v2\/posts\/783\/revisions\/786"}],"wp:attachment":[{"href":"https:\/\/gxb.webs.uvigo.es\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=783"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/gxb.webs.uvigo.es\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=783"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/gxb.webs.uvigo.es\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=783"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}